Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.
Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...
People with multiple system atrophy (MSA) generally have a very poor prognosis. Their median survival is 6.2 to 9.5 years after the first symptoms appear. Patients who are older at the time of onset ...
Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease ...
Multiple system atrophy (MSA) is a neurodegenerative disease that affects involuntary body functions such as blood pressure and heart rate as well as movement. It is similar to Parkinson's disease, ...
MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
The Food and Drug Administration (FDA) has granted Fast Track designation to verdiperstat (BVH-3241; Biohaven) for the treatment of multiple system atrophy. The Food and Drug Administration (FDA) has ...
Multiple system atrophy is a rare, progressive neurodegenerative condition for which there is currently no cure. Multiple system atrophy (MSA) is a progressive neurodegenerative disorder with an ...
This pilot open label study investigated the safety and preliminary efficacy of using IVIG over a 6-month period for treatment of MSA. IVIG treatment was well tolerated. Post-treatment functional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results